Recombinant Human Olfactory receptor 51E1 (OR51E1)

What is OR51E1 and where is it normally expressed?

OR51E1 (Olfactory Receptor Family 51 Subfamily E Member 1) belongs to the largest family of G protein-coupled receptors (GPCRs). While olfactory receptors are primarily expressed in nasal epithelium where they mediate the sense of smell, OR51E1 is an example of an ectopically expressed OR found in non-nasal tissues. OR51E1 has been detected in several tissues, with particularly notable expression in prostate tissue . The receptor demonstrates high evolutionary conservation, being approximately 95% identical to its mouse ortholog Olfr558, suggesting an essential physiological role beyond olfaction .

What are the known ligands for OR51E1?

OR51E1 is activated by short-chain to medium-chain organic acids (C3-C9), but not by acetate. Studies have confirmed that butyric acid activates OR51E1, leading to cAMP production and calcium influx . Specifically, among the aliphatic acids tested, eight compounds activated the receptor while seven did not, demonstrating specificity in the receptor's response . Additionally, nonanoic acid (NA) has been identified as an OR51E1 agonist with potential biological significance in cancer cell models .

How does OR51E1 signaling work at the molecular level?

Upon activation by appropriate ligands such as butyrate, OR51E1 stimulates adenylyl cyclase, leading to elevated intracellular cAMP levels. This has been consistently demonstrated through multiple methodologies, including indirect detection of PKA-mediated phosphorylation and direct measurement using fluorescence-based real-time cAMP biosensors . The receptor also triggers calcium influx upon activation . Olfactory G protein (Golf) has been shown to increase cAMP production induced by OR51E1 activation, although it does not affect receptor trafficking to the cell membrane .

What are the optimal expression systems for studying recombinant OR51E1?

Inducible expression systems have proven valuable for studying OR51E1, especially when investigating long-term effects of receptor upregulation. Due to potential cytotoxic effects of high OR51E1 expression in certain cell types, tetracycline-inducible promoter systems offer better control of expression levels. For detection purposes, augmenting OR51E1 cDNA with sequences that facilitate expression and adding epitope tags (e.g., FLAG) has been shown to improve both expression and detection efficiency . For functional analysis, human embryonic kidney 293 cells have been used successfully, as they don't appear to be affected by the cytotoxic effects observed in prostate cancer cell lines .

What methods are recommended for detecting OR51E1 protein expression?

Several complementary approaches are recommended for comprehensive OR51E1 detection:

• Immunohistochemistry: Effective for detecting both membranous and cytoplasmic OR51E1 protein expression in tissue samples

• Immunofluorescence microscopy: Using anti-FLAG antibodies with tagged recombinant OR51E1 to confirm cell surface localization and membrane trafficking

• Western blotting: For quantitative analysis of total protein expression levels

• Double immunofluorescence studies: Particularly useful for co-localization experiments, such as examining OR51E1 expression in VMAT1-positive cells

Researchers should be cautious with commercially available anti-GPCR antibodies, as their specificity and sensitivity can be problematic for OR51E1 detection .

How can OR51E1 functional activity be assessed in laboratory settings?

Multiple complementary approaches provide robust functional assessment:

• cAMP assays using both:

  • Indirect methods: Detecting PKA-mediated phosphorylation events downstream of cAMP production

  • Direct methods: Utilizing fluorescence-based real-time cAMP biosensors for dynamic measurements

• Calcium influx measurements: To detect secondary signaling events triggered by receptor activation

• Proliferation assays: Measuring changes in cell growth upon receptor activation or overexpression using standard proliferation assays (e.g., MTT, BrdU incorporation)

• Cell death assessment: Annexin V staining to quantify apoptosis following OR51E1 overexpression or activation

What regions of OR51E1 are crucial for proper trafficking and function?

Specific protein domains and amino acid residues significantly impact OR51E1 trafficking and function:

• N-terminal domain: Comparison between OR51E1 and its mouse ortholog Olfr558 revealed that despite 93% sequence identity, OR51E1 demonstrates significantly higher surface expression. Replacing the Olfr558 N-terminus with that of OR51E1 significantly increases trafficking, indicating the N-terminal region's critical role in surface expression .

• Key amino acid residues: The A156T mutation (a known single nucleotide polymorphism found primarily in South Asian populations) reduces both surface expression and cAMP production without altering total protein expression levels, highlighting the importance of specific residues in receptor function and trafficking .

• Transmembrane domains: Unlike the N-terminus, the transmembrane domains TM2, TM3, and TM4 do not appear to confer significant changes in surface expression when exchanged between orthologs .

How is OR51E1 expression altered in cancer tissues compared to normal tissues?

OR51E1 shows distinctive expression patterns in several cancer types:

• Prostate cancer: OR51E1 is significantly upregulated in prostate cancer compared to normal prostate tissue .

• Small intestine neuroendocrine carcinomas (SI-NECs): OR51E1 is differentially expressed in these tumors compared to normal tissue. Quantitative PCR analysis of laser-capture microdissected cells showed higher OR51E1 expression in SI-NEC cells than in adjacent microenvironment cells .

• Lung carcinoids: OR51E1 protein is expressed in 79% of typical carcinoids (TCs) and 86% of atypical carcinoids (ACs). Notably, in cases where all somatostatin receptor subtypes were lacking, membrane OR51E1 expression was still detected in 10 out of 17 TCs and 1 out of 2 ACs .

What is the evidence supporting OR51E1 as a potential cancer biomarker?

Multiple lines of evidence support OR51E1's potential as a cancer biomarker:

• Consistent detection in specific tumor types: Immunohistochemical studies detected both membranous and cytoplasmic OR51E1 protein expression in primary SI-NECs and metastases. Specifically, 18/43 primary tumors, 7/28 mesentery metastases, and 6/18 liver metastases showed OR51E1 positivity in more than 50% of tumor cells .

• Complementary to existing markers: In lung carcinoid cases where somatostatin receptor subtypes were absent (limiting diagnostic options), OR51E1 was still detected in a significant proportion of tumors. Higher OR51E1 immunohistochemical scores were detected in 5 out of 6 OctreoScan-negative lung carcinoid lesions .

• Potential for metastatic detection: OR51E1 protein expression has been documented in both primary tumors and metastatic sites, suggesting utility for monitoring disease progression .

• Detection in prostate cancer: Studies have identified OR51E1 as a novel mRNA tissue marker for prostate cancers, with more recent work confirming protein expression .

What functional effects does OR51E1 activation or overexpression have on cancer cells?

OR51E1 demonstrates significant anti-cancer properties:

• Growth suppression: Stimulation of LNCaP (prostate cancer) cells with butyrate inhibits growth, with knockdown of endogenous OR51E1 negating this cytostatic effect. Most significantly, overexpression of OR51E1 suppresses LNCaP cell proliferation .

• Signaling pathway alterations: Overexpression of OR51E1 causes upregulation of cytostatic and cell death markers including p27, p21, and p53. It also strongly increases annexin V staining (indicating apoptosis) and stimulates extracellular signal-regulated protein kinases 1 and 2 .

• Specific cytotoxicity: The growth inhibition and cytotoxic effects appear to be specific to certain cancer cell types. For example, OR51E1 overexpression and/or activation did not affect human embryonic kidney 293 cell proliferation, indicating that cytotoxicity is specific for certain cell types like LNCaP .

• Nonanoic acid effects: Treatment with the OR51E1 agonist nonanoic acid results in phosphorylation of various protein kinases, suggesting complex downstream signaling cascades that may mediate growth suppression .

What challenges might researchers encounter when working with recombinant OR51E1?

Several technical challenges should be anticipated:

• Cytotoxicity in stable cell lines: Research has shown that high levels of OR51E1 can be toxic to cells, resulting in selection of only clones where expression was suppressed. This necessitates the use of inducible expression systems for long-term studies .

• Membrane trafficking issues: Like many GPCRs, OR51E1 may face trafficking challenges. Researchers have found it beneficial to augment the OR51E1 cDNA with sequences that facilitate receptor expression and add detection tags .

• Antibody reliability: Commercial anti-GPCR antibodies often lack specificity and sensitivity, creating detection challenges. Using epitope-tagged recombinant proteins provides a more reliable alternative for detection .

• Functional assay selection: Different functional assays may yield varying results depending on cell type. For comprehensive characterization, multiple complementary approaches (cAMP assays, calcium imaging, proliferation studies) should be employed .

How can researchers distinguish OR51E1 from the closely related OR51E2?

Despite similarities, OR51E1 and OR51E2 show distinct characteristics:

• Ligand specificity: OR51E1 is activated by short-chain to medium-chain organic acids (C3-C9) but not by acetate. In contrast, OR51E2 responds to acetate and propionate but not to longer chain organic acids .

• Sequence analysis: While sharing approximately 60% sequence identity, molecular cloning and sequence analysis can definitively distinguish between these receptors. PCR using specific primers (e.g., forward primer 5′-TCA GCT TCT TCA TGA TGG TGG-3′ and reverse primer 5′-CAC TGA CAC CTA GGG CTC TGA-3′ for OR51E1) followed by sequence verification against GenBank published data provides reliable identification .

• Expression pattern analysis: While both receptors are expressed in prostate cancer, their distribution in other tissues and cancers may differ, providing another means of distinction .

What is the potential of OR51E1 as a therapeutic target in cancer?

OR51E1 shows promising characteristics as a therapeutic target:

• Anti-proliferative effects: Activation of OR51E1 by appropriate ligands or its overexpression suppresses cancer cell proliferation in specific cell types, suggesting potential therapeutic applications .

• Specificity for certain cancer types: The cytostatic and cytotoxic effects appear to be specific to certain cancer cell types, potentially allowing for targeted approaches .

• Potential for targeted therapy development: In SI-NECs, researchers have suggested OR51E1's potential for therapeutic molecular target development using solid tumor radioimmunotherapy . Similarly, for prostate cancer, the receptor might represent a promising alternative or combinatorial target, especially for advanced diseases where conventional treatments fail .

• Signaling pathway interactions: OR51E1 activation leads to upregulation of tumor suppressor proteins (p27, p21, p53) and stimulates key signaling pathways, providing multiple potential mechanisms for therapeutic intervention .

How might OR51E1 be utilized in combination with existing cancer therapies?

Potential integration strategies with current therapies include:

• Combination with androgen-deprivation therapy (ADT): For prostate cancer, where the androgen receptor plays a key role, OR51E1-targeted therapies could potentially complement ADT, especially for advanced diseases developing castration resistance .

• Alternative for somatostatin analog-resistant cases: In neuroendocrine tumors where somatostatin analogs (SSAs) are standard therapy, OR51E1 targeting might provide alternatives for patients with SSA-resistant disease. This is particularly promising given that OR51E1 is expressed in tumors lacking somatostatin receptor expression .

• Biomarker-guided therapy selection: OR51E1 expression levels could potentially serve as predictive biomarkers for response to certain therapies, allowing for more personalized treatment approaches .

• Development of dual-targeting approaches: Given OR51E1's expression in various cancer types, combination therapies targeting both OR51E1 and other cancer-specific pathways might enhance efficacy while reducing resistance development.